Mylan N Financial Indicators Patterns

MYL -- USA Stock  

USD 19.03  0.14  0.73%

You can employ fundamental analysis to find out if Mylan N V is mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We found thirty-six available fundamentals for Mylan N which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Mylan N V fundamentals including its Price to Book, Current Ratio, Retained Earnings, as well as the relationship between Net Income and Price to Earnings To Growth . Given that Mylan N V has Number of Shares Shorted of 8.55M, we recommend you check Mylan N last-minute market performance to make sure the company can sustain itself down the road. Use Mylan N to protect your portfolios against small markets fluctuations. The stock experiences moderate downward daily trend and can be a good diversifier. Check odds of Mylan N to be traded at $18.65 in 30 days.
50%50%

Chance of Financial Distress

Mylan N V has    50 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Mylan N Company Summary

Mylan N competes with Elanco Animal, Endo International, ESSA Pharma, and Evoke Pharma. Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter pharmaceutical products in North America, Europe, and internationally. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Mylan N operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 35000 people.

Mylan N Price to Earnings To Growth vs Cash per Share

Mylan N V is regarded second in price to earnings to growth category among related companies. It is regarded fourth in cash per share category among related companies fabricating about  0.59  of Cash per Share per Price to Earnings To Growth. The ratio of Price to Earnings To Growth to Cash per Share for Mylan N V is roughly  1.69 

Mylan N V Systematic Risk

The output start index for this execution was fourteen with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Mylan N V correlated with the market. If Beta is less than 0 Mylan N generally moves in the opposite direction as compared to the market. If Mylan N Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mylan N V is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mylan N is generally in the same direction as the market. If Beta > 1 Mylan N moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Mylan N Thematic Clasifications

Obamacare Repeal Idea
Obamacare RepealView
Obamacare Idea
ObamacareView
Drugs Idea
DrugsView

Mylan N May 24, 2019 Opportunity Range

Please see also Stocks Correlation. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Search macroaxis.com